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Abstract 
 
Market and industry reports can be useful in studying access to medicines from a 
pharmaceutical market perspective. However, many market and industry reports lack some or 
much of the information required to conduct analyses to study access to medicines and are 
often not transparent in their data sources and research methodologies. The instrument 
developed in this study, titled the Pharmaceutical Market and Industry Report Assessment Tool 
(PIRAT), assesses the quality of pharmaceutical market and industry reports, specifically 
focusing on the needs of public health researchers, and includes criteria describing the content 
and quality of the market reports. The assessment tool generates an unweighted score 
indicating the relative strengths and weaknesses of reports. 
 
Introduction 
 
Access to medicines is a complex, global problem impacted by many factors. Pharmaceutical 
market studies provide an opportunity to identify market interventions and policy solutions to 
improve access to medicines. By understanding the market and looking at the way the players 
interact on a national or global scale, researchers can learn about how these dynamics impact 
products in a market.  
 
Many market research studies are conducted by full service market intelligence companies, with 
findings published in market and industry reports. Although there are sometimes slight 
differences between market reports and industry reports, for the purposes of this instrument and 
study, the terms are used interchangeably.  
 
Pharmaceutical market and industry reports typically have a geographic focus and product 
group focus. The geographic focus can be national, regional or global. The product group focus 
can be a specific product, a disease treatment, or pharmaceuticals generally. Market and 
industry reports published by different companies contain slightly different information. However, 
most reports reviewed included a core set of topics, including: product and manufacturer 
information, product pipeline by manufacturer, epidemiological data, health system data, value 
share of specific companies, and total pharmaceutical market value. 
 
The major strength of pharmaceutical market and industry reports as a data source is their 
specificity to studying access to medicines from a pharmaceutical market perspective. They 
provide information focused specifically on pharmaceutical markets. However, there are also 
significant limitations to these reports. Many are very expensive (costing hundreds or thousands 
of dollars) and thus inaccessible to researchers, particularly in low and middle income countries. 
Additionally, reports sometimes do not contain relevant or necessary public health information 
(Wirtz et al. 2016). Reports are often not available describing the markets of low and middle 
income countries, making it difficult to describe the markets where there is a huge need to 
improve access (Leisinger et al. 2012). Furthermore, some reports do not cite sources or 
include a transparent and reproducible research methodology. Poor quality reports can 
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undermine the credibility of both the report itself and any research results derived from the 
reports.  
 
While market reports are a useful source for studying access to medicines, there is a need both 
to address the limitations of using market reports for public health research and to 
systematically evaluate the quality of market reports. Tools regarding related topics have been 
developed; the Access to Medicines Foundation has an index rating the practices of 
pharmaceutical companies and the World Health Organization has developed a method of 
analyzing pharmaceutical advertisements (Access to Medicines Foundation, 2016; World Health 
Organization, 1988). No existing tools, instruments, or measures of assessing the content or 
quality of market reports have been identified. Thus, this document attempts to fill that need. 
 
Methods 
 
An instrument to aid public health researchers in assessing the quality of pharmaceutical market 
and industry reports for the purposes of studying access to medicines was developed. Criteria 
were informed by the data used in access to medicines literature, understanding of the gaps in 
reviewed market reports, and the authors’ expertise. Pharmaceutical market and industry 
reports include similar information and are typically formatted in a similar manner regardless of 
their geographic and product group focus, and therefore can be assessed on mostly the same 
criteria. At the same time, differences in these reports were taken into consideration when 
developing the instrument.  
 
This tool is based on similar quality guidelines, such as the World Health Organization’s 
recommended guidelines on pharmaceutical advertisements and criteria on scientific rigor 
(World Health Organization, 1988; Langbein et al. 2006). Public health experts familiar with 
studying access to medicines from a pharmaceutical market perspective were consulted in 
developing the criteria for the instrument. After finalizing the assessment tool, four 
pharmaceutical market and industry reports were assessed to demonstrate the feasibility of the 
assessment tool; the assessment of these reports is attached in Annex 1. 
 
The Pharmaceutical Market and Industry Report Assessment Tool  
 
Titled the Pharmaceutical Market and Industry Report Assessment Tool (PIRAT), this 
instrument is a scored checklist describing the content and quality of a pharmaceutical market 
report. The PIRAT was designed to be calculated by an individual researcher. The majority of 
criteria are scaled on a (0 no, 1 sometimes/somewhat, 2 yes) scale, with some exceptions, 
indicated with each criterion. Decimal scores are accepted at the discretion of each researcher, 
with clarification notes requested for such scores (see examples in Annex 1). All criteria are 
weighted equally. 
 
The PIRAT is divided into two parts: the Content Score and the Quality Score. The maximum 
possible score for all reports is 80 (40 points for the Content Score and 40 the points for Quality 
Score). Pharmaceutical market and industry reports that focus on a specific product (e.g. 
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insulin) also have a related Content Sub-Score (20 points), and their maximum possible score is 
100. 
   
The Content Score assesses whether a pharmaceutical market report provides sufficient 
information on key dimensions of the pharmaceutical market desired by public health 
professionals studying access to medicines. This can serve as a valuable indicator for public 
health researchers, suggesting whether or not they need further supporting materials. 
 
The Quality Score describes the scientific rigor of a market report. This score gives insight into 
whether the information in the study is supported and reviewed by experts and contacts in the 
field, whether the data collected was representative and credible, and whether the methods 
used in the study were rigorous and reproducible. The Quality Score can indicate the extent of 
the limitation of the report. 
 
The following section includes a description and analysis of each of the categories of criteria 
used in assessing reports with this tool.  
 
Content Score 
 
Title and Executive Summary Information: Criteria 1-2 
It is important that the title and/or executive summary include both the geographical focus and 
the product group focus of the report. As pharmaceutical advertisements should include the 
name of the product being promoted based on criteria used by the World Health Organization, it 
is reasonable that the titles or executive summaries of pharmaceutical market and industry 
reports should include the region and product group of focus (World Health Organization, 2010). 
A time period is also necessary to provide context to the information being presented. Without 
this context given, the information presented is of little use to analyzing pharmaceutical markets. 
 
Public Health and Epidemiology Data: Criteria 3-6 
Data on the epidemiology of diseases in the region of study is important to understand the 
health needs in the region and the demand for the pharmaceutical of study. Without data on 
disease burden, the demand described in a market report lacks credibility. Prevalence and 
incidence data, which describe the disease burden and are comparable between populations, 
should also be included. To accurately estimate demand, the size of the population and/or the 
number of people with the disease of study should be provided. This helps to identify how much 
of the pharmaceutical is needed by the population of study, and what barriers might be present.  
 
Further information on burden of disease is also needed to get a full understanding of the region 
of study. Mortality, morbidity, and disability adjusted life years, for example, help to quantify the 
impact of a disease on a population. Many conditions often have related co-morbidities; for 
example, diabetes and cardiovascular disease are often present in the same individual (Mo et 
al. 2006). These co-morbidities may require additional medications, which can compound 
difficulties in accessing and affording medicines. Because of this, it is important for market 
reports to include information not only on the disease of study but on related diseases. 
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Pharmaceutical Market Volumes and Values: Criteria 7-10 
Information on volume is important in order to estimate whether the current supply of medicines 
meets the demand. Volume data can both give insight into the number of people the market can 
currently provide and thus treat (total volume) as well as the impact each player has in providing 
for the population (volume share).  
 
Value is a product of price multiplied by volume. The value shows the economic impact of the 
pharmaceutical market and in conjunction with market shares of companies can help describe 
the market landscape and competition. This is necessary to understand the impact of the 
market and the power of the different players in the pharmaceutical market. It also gives an 
indicator of the price of the product if the volume is known. Ideally, market values and volumes 
would be broken down into the private sector and public sector, as this information is particularly 
important in understanding the pharmaceutical markets in low and middle income countries. In 
addition, price information should include information on the percentage mark-ups in the supply 
chain and other factors that influence the consumer price.  
 
Key Players (Manufacturers of Final Formulation/Pharmaceutical Product and Related 
Companies): Criteria 11-3 
Knowing the key players of the pharmaceutical market is necessary to understand the supply. 
The key players, or pharmaceutical manufacturers of the originator and their associated 
licensed manufacturers, subsidiaries, and distributors, provide products to the pharmaceutical 
market and can be a key part of the solution to supply side barriers. Furthermore, to analyze 
competition in the market and the opportunities to lower product prices, it is important to know 
about business relationships and partnerships between companies. Thus, it is necessary to 
have licensed manufacturers, subsidiaries, and distributors differentiated from manufacturers in 
reports. 
 
Product and Patent Information: Criteria 14-7 
Originator products are the pharmaceutical products, usually under a patent, sold by the original 
company that identified the molecule or marketed the product. Generic products are chemically 
identical to the originator product but produced by other manufacturers than the originator 
product, usually at a lower price. Having information about the products in the market, their 
associated patents, and whether or not there are generics in the market or if there is the 
opportunity for generics to enter the market allows for analysis of these potential legal and 
market barriers or opportunities. Information on the diagnostics used to deliver the 
pharmaceutical of study (e.g. syringe, pen, or pump for insulin) is also important for many 
pharmaceuticals (excluding oral dosage systems), and should be included. 
 
Additional Criteria: 18-20 
Analyses of competition in the pharmaceutical market are important in identifying the market 
breakdown, the most important key players in terms of market impact and power, and the 
current dynamics in the pharmaceutical market. Competition analyses should be included as 
sections in the report describing not only the market shares of each key player but also how 
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market, political, and other external factors affect the market’s competitive landscape, and how 
the interactions between companies result in market opportunities. When studying access to 
medicines, it is important to understand the competition to identify opportunities and challenges 
in relation to availability and affordability of medicines. Market forecasts are needed to identify 
changes in the market, particularly in the value, volume, key players, and overall landscape of 
the pharmaceutical market. Detailed descriptions included in the report on opportunities and 
challenges are also exceptionally valuable and necessary.  
 
Content Sub-Score (Product-Specific) 
 
Product-specific pharmaceutical market reports provide more specific information on the market 
of an individual pharmaceutical product (e.g. metformin, insulin). The content sub-score for 
product-specific reports describes criteria that would be ideally included in a product-specific 
pharmaceutical market report, but would typically be beyond the scope of a disease-focused or 
general pharmaceutical report. 
 
Production Volume and Value, Supply and Demand: Criteria 21-6 
Total production volume and value can help to identify or calculate whether or not current 
production is adequate for the population. This calculation also requires an estimation of the 
need based on the disease prevalence or clinical assessment, which should be included in the 
report. Having these production values by country and company is even more valuable, showing 
whether local production is large enough to serve the local population or whether there is 
importing. This can also indicate whether trade network studies would be a valuable addition to 
market analyses. 
 
Additional Criteria: Criteria 27-30 
Understanding the competition in a pharmaceutical market and the market shares beyond 
criteria 9 (total market value) and 10 (market shares by company) requires more product-
focused data. Knowing the market share by product helps to understand which products are 
most impactful and important to populations in the market, while knowing the company shares 
for this specific product demonstrate which companies have the greatest involvement in a 
product’s market. Both can give insight into opportunities to promote access to medicines in a 
market and identify key players that should be involved in developing a solution. 
 
New products in a pipeline are important to product reports as they show how the market 
landscape could change in the future, influencing existing products, pricing, and prescribing 
behaviors. With new companies and products entering a market come new opportunities and 
challenges to improve access to medicines. 
 
Affordability is also a major component of access to medicines. Information on access schemes 
by individual companies or at the country level are important to describing what health actors 
are doing to improve access to medicines. 
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Quality Score 
 
References and Data Sources: Criteria 31-40 
It is important to include and describe the sources used in conducting studies. Referencing 
promotes transparency in research and allows for verification. Clear references are necessary in 
any high quality research report, and pharmaceutical market and industry reports should be no 
different. In this instrument, reports gain points for citing themselves rarely and citing scientific, 
peer-reviewed literature and accessible gray literature. 
 
Resources discussing the quality and rigor of scientific research assert the importance of using 
a broad, representative data sample (Laingbein et al. 2006). It is therefore important to consult 
data sources from multiple sectors in describing the pharmaceutical market. For pharmaceutical 
market reports, private sector and industry resources (such as pharmaceutical companies), 
public sector and government resources (such as ministries of health), and provider, hospital, 
and insurance resources (such as doctors or hospital administrators), all key players in the 
health sector, should be consulted. Even with representative data samples, there are limitations 
to every study. These limitations should be clearly described in the market report. 
 
While market research companies may have expertise in the industry being described, it is 
important to consult with experts and technical contacts working in the field. The instrument 
includes whether or not experts were consulted and whether technical contacts who worked on 
the report are cited. 
 
Research Methodology and Presentation: Criteria 41-7 
It is important that research is systematic, reproducible, and rigorous. To ensure this, 
pharmaceutical market and industry reports should include a research methodology for the 
study, including a description of the primary and secondary sources used and the data analyses 
conducted. Ideally, the research methodology would be detailed so that the study is clear, 
comprehensive, and reproducible, supporting the validity and rigor of the study. 
 
The presentation of the report is also important to the clarity and validity of the study. Accepted 
pharmaceutical terminology for active ingredients and products, specifically the international 
nonproprietary name (INN), should be used so that the content is clear. Using accepted 
scientific units in reporting the data (e.g. Daily Defined Dose (DDD) or Standard Unit (SU)) is 
also important, as it lends itself to verification and further analyses regarding demand and 
volume. Additionally, it supports the expertise of the authors; reports without valid units make 
the reader question whether or not the authors are qualified to report on the area of study. 
Graphs, tables, and figures must also be presented in a clear, legible, and understandable 
manner. 
 
Company Background: Criteria 48-50 
Accountability is necessary to support the validity of pharmaceutical market reports. Other 
instruments, including the World Health Organization’s assessment criteria for pharmaceutical 
advertisements, require that the company publishing the report include name and address 
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(World Health Organization, 1988). Market and industry reports should follow the same rules 
and clearly include the name of the market research company, address, and contact information 
for the company and/or specific authors. This adds to the credibility and verifiability of the study. 
 
Discussion 
 
This instrument aims to support public health researchers conducting studies of access to 
medicines from a pharmaceutical market perspective using pharmaceutical market and industry 
reports and public health professionals consulting pharmaceutical market and industry reports to 
understand a market. As there are often limitations to using market reports in public health 
studies, this instrument allows researchers to systematically assess the strengths and 
weaknesses of these reports. 
 
Ideally, market report companies would use these guidelines to tailor their reports and improve 
the content and quality of their reports for readers of various disciplines and improve the 
transparency of the sources and methodologies employed in compiling these reports. A more 
realistic result of this assessment tool, and future improvements upon it, would be for public 
health professionals to consult the assessment tool when reading pharmaceutical market and 
industry reports and for public health researchers to use this instrument when conducting 
studies of pharmaceutical markets. 
 
Limitations 
 
There are some limitations to the instrument and areas for future improvement. First, the tool 
does not weigh each of the item in relation to their relevance which affect the overall score. For 
instance, missing the address of a pharmaceutical company or market intelligence company 
may be seen as less relevant than missing the volume of the pharmaceutical market of study. 
Additional revisions to this tool could find a method of ranking the importance of the different 
criteria and weighting the score based on their relevance. A second limitation is that the tool 
does not assess public and private sector information separately. Stratification by public and 
private sector is relevant in low and middle income countries. As differentiating the public and 
private sector was not included in reports reviewed, it was not included as a criterion in this 
assessment tool. Furthermore, the tool does not assess whether reports include regulatory 
information such as average decision time from market authorization application to market 
authorization. A revised version of the tool could include stratification by sector and assessing 
the extent to which regulatory information is included. Finally, while this instrument has been 
reviewed by a small group of public health experts, it has not been reviewed for validity by 
outside experts in public health or market research. This instrument should be reviewed, 
validated, and improved upon by other relevant experts. 
 
Conclusion 
 
The Pharmaceutical Market and Industry Report Assessment Tool is a feasible method to 
identify the strengths and weaknesses of a pharmaceutical market and industry report. This 
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assessment tool is a first step in assessing the limitations of pharmaceutical market reports as a 
source in studying access to medicines and will support future studies of pharmaceutical 
markets. 
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Annex  
 
PIRAT Score for the Beijing Hengzhou Bozhi International Information Consulting Co., 
(QY Research): Global and Chinese Insulin Industry Report, November 2014 [1] 
 
Final Score (Out of 80): 44.5                
Product-Specific Score (Out of 100) 56.5 
 
Content Score 
Total 
Score: 
25.5/40 
Important 
Notes 
Title and Executive Summary Information 
1 
Does the report title or executive summary 
include the geographic focus (country, region, 
global, other) and product group focus (general 
pharmaceutical, disease, product, other)? 
(0 no, 1 
somewhat, 2 yes) 2   
2 
Does the report title or executive summary 
include a year or time period the report 
describes? 
(0 no, 1 
somewhat, 2 yes) 2   
Public Health and Epidemiology Data 
3 
Does the report describe the prevalence and/or 
incidence of major diseases or the disease of 
study?  
(0 no, 1 
somewhat, 2 yes) 0   
4 
Does the report include the size of the 
population of major diseases or the disease of 
study?  
(0 no, 1 
somewhat, 2 yes) 1.5 
While the 
information 
was 
present, it 
was not 
clearly 
available or 
easy to find 
in the 
report. 
Thus, a 
half point 
was 
deducted. 
5 
Does the report include information on the 
burden of disease (mortality, morbidity, 
disability adjusted life years, etc.) for the 
disease of study? 
(0 no, 1 
somewhat, 2 yes) 0   
6 
Does the report include information on the 
burden of disease (mortality, morbidity, 
disability adjusted life years, etc.) for 
conditions not the focus of the report? 
(0 no, 1 
somewhat, 2 yes) 0   
Pharmaceutical Market Volumes and Values 
7 
Does the report include the total market 
volume?  
(0 no, 1 
somewhat, 2 yes) 1 
8 
Does the report include the market volume 
share of each company? 
(0 no, 1 
somewhat, 2 yes) 2   
9 Does the report include the total market value? 
(0 no, 1 
somewhat, 2 yes) 2   
10 
Does the report include the market value shares 
of each company?  
(0 no, 1 
somewhat, 2 yes) 2   
Key Players (Manufacturers of Final Formulation/Pharmaceutical Product and Related 
Companies) 
11 
Are the manufacturers described in the 
report? 
(0 no, 1 
somewhat, 2 
yes) 2   
12 
Are licensed manufacturers, subsidiaries, and 
distributors described in the report? 
(0 no, 1 
somewhat, 2 
yes) 1   
13 
Are licensed manufacturers, subsidiaries, and 
distributors differentiated from 
manufacturers? 
(0 no, 1 
somewhat, 2 
yes) 1   
Product and Patent Information 
14 
Are the originator and/or branded products 
relevant to the disease or population of study 
included in the report? 
(0 no, 1 
somewhat, 2 
yes) 2   
15 
Are the specific patents of the originator 
and/or branded products mentioned? 
(0 no, 1 
somewhat, 2 
yes) 1   
16 
Are generic medicines included relevant to 
the disease or population of study included in 
the report? (Or, do the patents described in 15 
specify that they are still in effect?) 
(0 no, 1 
somewhat, 2 
yes) 1   
17 
Are the patents of the diagnostics which are 
used to deliver the medicines mentioned? (If 
not applicable, such as for oral dosage 
systems, give full points and note in 
comments N/A). 
(0 no, 1 
somewhat, 2 
yes) 1 
Additional Criteria 
18 
Does the report include analyses of 
competition in the pharmaceutical market? 
(0 no, 1 
somewhat, 2 
yes) 2   
19 
Does the report include opportunities and 
challenges present in the pharmaceutical 
market? 
(0 no, 1 
somewhat, 2 
yes) 2   
20 
Does the report provide a pharmaceutical 
market forecast? 
(0 no, 1 
somewhat, 2 
yes) 0   
 
Content Sub-Score (Product Specific) 
Total 
Score: 
12/20 
Important 
Notes 
Production Volume and Value, Supply and Demand 
21 
Is the production value by manufacturer 
included? 
(0 no, 1 
somewhat, 2 
yes) 2   
22 Is the production value by country included? 
(0 no, 1 
somewhat, 2 
yes) 0   
23 
Is the production volume by manufacturer 
included? 
(0 no, 1 
somewhat, 2 
yes) 2   
24 
Is the production volume by country 
included? 
(0 no, 1 
somewhat, 2 
yes) 2   
25 
Is the estimated total production (supply) 
included? 
(0 no, 1 
somewhat, 2 
yes) 2   
26 
Is the estimation of need (demand) based on 
disease prevalence or clinical assessment 
included?  
(0 no, 1 
somewhat, 2 
yes) 1   
Additional Criteria 
27 Is the market share by product included? 
(0 no, 1 
somewhat, 2 
yes) 1 
28 Is the market share by company included? 
(0 no, 1 
somewhat, 2 
yes) 2   
29 Are new products in the pipeline described? 
(0 no, 1 
somewhat, 2 
yes) 0   
30 
Is any type of access scheme (e.g. tiered 
pricing, voluntary licensing, donation) 
described? 
(0 no, 1 
somewhat, 2 
yes) 0   
  
Quality Score 
Total 
Score: 
19/40 
Important 
Notes 
References and Data Sources 
31 
Does the report reference itself/the market 
research company?  
(0 only/often, 1 
sometimes, 2 
never/rarely) 0   
32 
Does the report reference scientific, peer-
reviewed literature? 
(0 never/rarely, 
1 sometimes, 2 
often) 0   
33 
Does the report reference gray literature (non-
peer-reviewed)?  
(0 never/rarely, 
1 sometimes, 2 
often) 0   
34 
Are the limitations of the data sources 
discussed?  
(0 no, 1 
somewhat, 2 
yes) 0   
35 
Are sources clearly cited and referenced in the 
report? 
(0 no, 1 
somewhat, 2 
yes) 0.5 
The citations 
are not clear; 
only general 
citations 
referencing the 
publishing 
market 
research 
company or 
the 
pharmaceutical 
companies 
referenced in 
the text of the 
table are 
included. 
36 
Are private sector/industry resources 
consulted? 
(0 no, 1 
somewhat, 2 
yes) 2   
37 
Are public sector/government resources 
consulted? 
(0 no, 1 
somewhat, 2 
yes) 2   
38 
Are provider/hospital/insurance resources 
consulted? 
(0 no, 1 
somewhat, 2 
yes) 0   
39 
Were experts consulted in compiling this 
report? 
(0 no, 1 
somewhat, 2 
yes) 0   
40 
Are technical contacts (with their place of 
work, sector of work, and position specified) 
included in this report? 
(0 no, 1 
somewhat, 2 
yes) 1 
Research Methodology and Presentation 
41 
Are the data sources (primary/secondary/etc.) 
clearly described and referenced?  
(0 no, 1 
somewhat, 2 
yes) 0.5 
References 
were vague 
and the 
categories of 
data sources 
are only 
generally 
described. 
42 Are the data analyses described?  
(0 no, 1 
somewhat, 2 
yes) 0.5 
The analyses 
used are stated 
in the 
methodology 
but not 
described in 
detail. 
43 
Is the general research methodology 
described? 
(0 no, 1 
somewhat, 2 
yes) 2   
44 
Is the research methodology clear, 
comprehensive, and reproducible? 
(0 no, 1 
somewhat, 2 
yes) 1 
45 Are accepted scientific units used? 
(0 never/rarely, 
1 sometimes, 2 
often/always) 1 
46 
Is accepted pharmaceutical terminology (for 
the active ingredient) used? 
(0 never/rarely, 
1 sometimes, 2 
often/always) 2   
47 
Are data graphs and figures presented in a 
clear, legible, and understandable manner? 
(0 never/rarely, 
1 sometimes, 2 
often/always) 1.5 
Some tables 
had unclear 
titles and used 
unclear 
terminology. 
Company Background 
48 
Is the name of the market research company 
clearly presented? 
(0 no, 1 
somewhat, 2 
yes) 2   
49 
Is the location/address of the market research 
company included? 
(0 no, 1 
somewhat, 2 
yes) 2   
50 
Is contact information for the company and/or 
authors included? 
(0 no, 1 
somewhat, 2 
yes) 1 
  
 
PIRAT Score for the Business Monitor International: China Pharmaceutical and 
Healthcare Industry Report Q2 2014 [2] 
 
Final Score (Out of 80): 43 
 
Content Score 
Total 
Score: 
27.5/40 
Important 
Notes 
Title and Executive Summary Information 
1 
Does the report title or executive summary 
include the geographic focus (country, 
region, global, other) and product group 
focus (general pharmaceutical, disease, 
product, other)? 
(0 no, 1 
somewhat, 2 
yes) 2   
2 
Does the report title or executive summary 
include a year or time period the report 
describes? 
(0 no, 1 
somewhat, 2 
yes) 2   
Public Health and Epidemiology Data 
3 
Does the report describe the prevalence 
and/or incidence of major diseases or the 
disease of study?  
(0 no, 1 
somewhat, 2 
yes) 1.5 
Not all major 
diseases are 
described, but 
those that are 
included are 
described 
clearly.  
4 
Does the report include the size of the 
population of major diseases or the disease 
of study?  
(0 no, 1 
somewhat, 2 
yes) 1 
5 
Does the report include information on the 
burden of disease (mortality, morbidity, 
disability adjusted life years, etc.) for the 
disease of study? 
(0 no, 1 
somewhat, 2 
yes) 1.5 
Not all desired 
burden of 
disease data is 
included, but 
there is 
comprehensive 
mortality data 
and some 
statistics on 
other relevant 
measures. 
6 
Does the report include information on the 
burden of disease (mortality, morbidity, 
disability adjusted life years, etc.) for 
conditions not the focus of the report? 
(0 no, 1 
somewhat, 2 
yes) 1.5 
Diseases in 
general are 
discussed 
because of the 
general 
pharmaceutical 
focus of the 
report, but 
specifics about 
related 
conditions are 
not included. 
Pharmaceutical Market Volumes and Values 
7 
Does the report include the total market 
volume?  
(0 no, 1 
somewhat, 2 
yes) 0   
8 
Does the report include the market volume 
share of each company? 
(0 no, 1 
somewhat, 2 
yes) 0   
9 
Does the report include the total market 
value? 
(0 no, 1 
somewhat, 2 
yes) 2   
10 
Does the report include the market value 
shares of each company?  
(0 no, 1 
somewhat, 2 
yes) 0   
Key Players (Manufacturers of Final Formulation/Pharmaceutical Product and Related 
Companies) 
11 
Are the manufacturers described in the 
report? 
(0 no, 1 
somewhat, 2 
yes) 2   
12 
Are licensed manufacturers, subsidiaries, 
and distributors described in the report? 
(0 no, 1 
somewhat, 2 
yes) 1   
13 
Are licensed manufacturers, subsidiaries, 
and distributors differentiated from 
manufacturers? 
(0 no, 1 
somewhat, 2 
yes) 1 
In  some cases, 
the local 
partners are 
differentiated 
from the 
manufacturer, 
or foreign firm. 
Product and Patent Information 
14 
Are the originator and/or branded products 
relevant to the disease or population of study 
included in the report? 
(0 no, 1 
somewhat, 2 
yes) 2   
15 
Are the specific patents of the originator 
and/or branded products mentioned? 
(0 no, 1 
somewhat, 2 
yes) 1.5 
There is a 
subsection 
specifically on 
patented 
products and 
some 
discussion of 
patents. 
16 
Are generic medicines included relevant to 
the disease or population of study included 
in the report? (Or, do the patents described 
in 15 specify that they are still in effect?) 
(0 no, 1 
somewhat, 2 
yes) 1.5 
There is a 
section on the 
generic 
medicines 
market, but not 
all relevant 
information is 
included. 
17 
Are the patents of the diagnostics which are 
used to deliver the medicines mentioned? (If 
not applicable, such as for oral dosage 
systems, give full points and note in 
comments N/A). 
(0 no, 1 
somewhat, 2 
yes) 1 
Additional Criteria     
18 
Does the report include analyses of 
competition in the pharmaceutical market? 
(0 no, 1 
somewhat, 2 
yes) 2   
19 
Does the report include opportunities and 
challenges present in the pharmaceutical 
market? 
(0 no, 1 
somewhat, 2 
yes) 2   
20 
Does the report provide a pharmaceutical 
market forecast? 
(0 no, 1 
somewhat, 2 
yes) 2   
 
Criteria 21-30 Not Applicable To This Report 
 
Quality Score 
Total 
Score: 
15.5/40 
Important 
Notes 
References and Data Sources 
31 
Does the report reference itself/the market 
research company?  
(0 only/often, 1 
sometimes, 2 
never/rarely) 0 
32 
Does the report reference scientific, peer-
reviewed literature? 
(0 never/rarely, 
1 sometimes, 2 
often) 0   
33 
Does the report reference gray literature 
(non-peer-reviewed)?  
(0 never/rarely, 
1 sometimes, 2 
often) 1 
34 
Are the limitations of the data sources 
discussed?  
(0 no, 1 
somewhat, 2 
yes) 0   
35 
Are sources clearly cited and referenced in 
the report? 
(0 no, 1 
somewhat, 2 
yes) 0   
36 
Are private sector/industry resources 
consulted? 
(0 no, 1 
somewhat, 2 
yes) 0 
37 
Are public sector/government resources 
consulted? 
(0 no, 1 
somewhat, 2 
yes) 1 
38 
Are provider/hospital/insurance resources 
consulted? 
(0 no, 1 
somewhat, 2 
yes) 0   
39 
Were experts consulted in compiling this 
report? 
(0 no, 1 
somewhat, 2 
yes) 0   
40 
Are technical contacts (with their place of 
work, sector of work, and position 
specified) included in this report? 
(0 no, 1 
somewhat, 2 
yes) 0   
Research Methodology and Presentation 
41 
Are the data sources 
(primary/secondary/etc.) clearly described 
and referenced?  
(0 no, 1 
somewhat, 2 
yes) 0   
42 Are the data analyses described?  
(0 no, 1 
somewhat, 2 
yes) 1.5 
Market 
forecasts and 
some economic 
analyses have 
their methods 
clearly 
described; the 
methodology as 
a whole is not 
clearly 
described. 
43 
Is the general research methodology 
described? 
(0 no, 1 
somewhat, 2 
yes) 0.5 
The general 
research 
methodology is 
vague, and only 
the market 
forecast model 
analysis is 
described. 
44 
Is the research methodology clear, 
comprehensive, and reproducible? 
(0 no, 1 
somewhat, 2 
yes) 0.5 
The market 
forecast model 
is clear and 
seems to be 
reproducible, 
but the general 
research 
methodology is 
not clear. 
45 Are accepted scientific units used? 
(0 never/rarely, 
1 sometimes, 2 
often/always) 2 
46 
Is accepted pharmaceutical terminology (for 
the active ingredient) used? 
(0 never/rarely, 
1 sometimes, 2 
often/always) 2   
47 
Are data graphs and figures presented in a 
clear, legible, and understandable manner? 
(0 never/rarely, 
1 sometimes, 2 
often/always) 2   
Company Background 
48 
Is the name of the market research company 
clearly presented? 
(0 no, 1 
somewhat, 2 
yes) 2   
49 
Is the location/address of the market 
research company included? 
(0 no, 1 
somewhat, 2 
yes) 2   
50 
Is contact information for the company 
and/or authors included? 
(0 no, 1 
somewhat, 2 
yes) 1 
PIRAT Score for the Frost & Sullivan: Chinese Pharmaceutical Market, May 2013 [3] 
 
Final Score (Out of 80): 32 
 
Content Score 
Total 
Score: 
17/40 
Important 
Notes 
Title and Executive Summary Information 
1 
Does the report title or executive summary 
include the geographic focus (country, region, 
global, other) and product group focus (general 
pharmaceutical, disease, product, other)? 
(0 no, 1 
somewhat, 2 yes) 2   
2 
Does the report title or executive summary 
include a year or time period the report 
describes? 
(0 no, 1 
somewhat, 2 yes) 2 
Public Health and Epidemiology Data 
3 
Does the report describe the prevalence and/or 
incidence of major diseases or the disease of 
study?  
(0 no, 1 
somewhat, 2 yes) 0   
4 
Does the report include the size of the 
population of major diseases or the disease of 
study?  
(0 no, 1 
somewhat, 2 yes) 0   
5 
Does the report include information on the 
burden of disease (mortality, morbidity, 
disability adjusted life years, etc.) for the 
disease of study? 
(0 no, 1 
somewhat, 2 yes) 0   
6 
Does the report include information on the 
burden of disease (mortality, morbidity, 
disability adjusted life years, etc.) for 
conditions not the focus of the report? 
(0 no, 1 
somewhat, 2 yes) 0   
Pharmaceutical Market Volumes and Values 
7 
Does the report include the total market 
volume?  
(0 no, 1 
somewhat, 2 yes) 0   
8 
Does the report include the market volume 
share of each company? 
(0 no, 1 
somewhat, 2 yes) 0   
9 Does the report include the total market value? 
(0 no, 1 
somewhat, 2 yes) 2   
10 
Does the report include the market value shares 
of each company?  
(0 no, 1 
somewhat, 2 yes) 1   
Key Players (Manufacturers of Final Formulation/Pharmaceutical Product and Related 
Companies) 
11 Are the manufacturers described in the report? 
(0 no, 1 
somewhat, 2 yes) 2   
12 
Are licensed manufacturers, subsidiaries, and 
distributors described in the report? 
(0 no, 1 
somewhat, 2 yes) 1   
13 
Are licensed manufacturers, subsidiaries, and 
distributors differentiated from manufacturers? 
(0 no, 1 
somewhat, 2 yes) 1   
Product and Patent Information 
14 
Are the originator and/or branded products 
relevant to the disease or population of study 
included in the report? 
(0 no, 1 
somewhat, 2 yes) 1   
15 
Are the specific patents of the originator and/or 
branded products mentioned? 
(0 no, 1 
somewhat, 2 yes) 0   
16 
Are generic medicines included relevant to the 
disease or population of study included in the 
report? (Or, do the patents described in 15 
specify that they are still in effect?) 
(0 no, 1 
somewhat, 2 yes) 0   
17 
Are the patents of the diagnostics which are 
used to deliver the medicines mentioned? (If 
not applicable, such as for oral dosage systems, 
give full points and note in comments N/A). 
(0 no, 1 
somewhat, 2 yes) 0   
Additional Criteria     
18 
Does the report include analyses of competition 
in the pharmaceutical market? 
(0 no, 1 
somewhat, 2 yes) 2   
19 
Does the report include opportunities and 
challenges present in the pharmaceutical 
market? 
(0 no, 1 
somewhat, 2 yes) 2   
20 
Does the report provide a pharmaceutical 
market forecast? 
(0 no, 1 
somewhat, 2 yes) 1   
 
Criteria 21-30 Not Applicable To This Report 
 
Quality Score 
Total 
Score: 
15/40 
Important 
Notes 
References and Data Sources 
31 
Does the report reference itself/the market 
research company?  
(0 only/often, 1 
sometimes, 2 
never/rarely) 0   
32 
Does the report reference scientific, peer-
reviewed literature? 
(0 never/rarely, 1 
sometimes, 2 
often) 0   
33 
Does the report reference gray literature (non-
peer-reviewed)?  
(0 never/rarely, 1 
sometimes, 2 
often) 0   
34 
Are the limitations of the data sources 
discussed?  
(0 no, 1 
somewhat, 2 yes) 0   
35 
Are sources clearly cited and referenced in the 
report? 
(0 no, 1 
somewhat, 2 yes) 0   
36 Are private sector/industry resources consulted?
(0 no, 1 
somewhat, 2 yes) 1   
37 
Are public sector/government resources 
consulted? 
(0 no, 1 
somewhat, 2 yes) 0   
38 
Are provider/ hospital/insurance resources 
consulted? 
(0 no, 1 
somewhat, 2 yes) 0   
39 
Were experts consulted in compiling this 
report? 
(0 no, 1 
somewhat, 2 yes) 0   
40 
Are technical contacts (with their place of 
work, sector of work, and position specified) 
included in this report? 
(0 no, 1 
somewhat, 2 yes) 0   
Research Methodology and Presentation 
41 
Are the data sources (primary/secondary/etc.) 
clearly described and referenced?  
(0 no, 1 
somewhat, 2 yes) 0   
42 Are the data analyses described?  
(0 no, 1 
somewhat, 2 yes) 1   
43 Is the general research methodology described? 
(0 no, 1 
somewhat, 2 yes) 1   
44 
Is the research methodology clear, 
comprehensive, and reproducible? 
(0 no, 1 
somewhat, 2 yes) 0   
45 Are accepted scientific units used? 
(0 never/rarely, 1 
sometimes, 2 
often/always) 2   
46 
Is accepted pharmaceutical terminology (for the 
active ingredient) used? 
(0 never/rarely, 1 
sometimes, 2 
often/always) 2   
47 
Are data graphs and figures presented in a 
clear, legible, and understandable manner? 
(0 never/rarely, 1 
sometimes, 2 
often/always) 2   
Company Background 
48 
Is the name of the market research company 
clearly presented? 
(0 no, 1 
somewhat, 2 yes) 2   
49 
Is the location/address of the market research 
company included? 
(0 no, 1 
somewhat, 2 yes) 2   
50 
Is contact information for the company and/or 
authors included? 
(0 no, 1 
somewhat, 2 yes) 2   
PIRAT Score for the Kalorama Information: Pharmaceutical Markets in BRIC, July 2008 
[4] 
 
Final Score (Out of 80): 47.5 
 
Content Score 
Total 
Score: 
21.5/40 
Important 
Notes 
Title and Executive Summary Information 
1 
Does the report title or executive summary 
include the geographic focus (country, region, 
global, other) and product group focus 
(general pharmaceutical, disease, product, 
other)? 
(0 no, 1 
somewhat, 2 yes) 2   
2 
Does the report title or executive summary 
include a year or time period the report 
describes? 
(0 no, 1 
somewhat, 2 yes) 2 
Public Health and Epidemiology Data 
3 
Does the report describe the prevalence and/or 
incidence of major diseases or the disease of 
study?  
(0 no, 1 
somewhat, 2 yes) 1 
4 
Does the report include the size of the 
population of major diseases or the disease of 
study?  
(0 no, 1 
somewhat, 2 yes) 1 
5 
Does the report include information on the 
burden of disease (mortality, morbidity, 
disability adjusted life years, etc.) for the 
disease of study? 
(0 no, 1 
somewhat, 2 yes) 1.5 
The leading 
causes of 
death and 
statistics 
related to 
mortality 
are 
included. 
6 
Does the report include information on the 
burden of disease (mortality, morbidity, 
disability adjusted life years, etc.) for 
conditions not the focus of the report? 
(0 no, 1 
somewhat, 2 yes) 1.5 
There is no 
specific 
disease 
focus, but 
the leading 
causes of 
death and 
mortality 
statistics are 
included. 
Pharmaceutical Market Volumes and Values 
7 
Does the report include the total market 
volume?  
(0 no, 1 
somewhat, 2 yes) 0   
8 
Does the report include the market volume 
share of each company? 
(0 no, 1 
somewhat, 2 yes) 0   
9 Does the report include the total market value? 
(0 no, 1 
somewhat, 2 yes) 2   
10 
Does the report include the market value 
shares of each company?  
(0 no, 1 
somewhat, 2 yes) 0   
Key Players (Manufacturers of Final Formulation/Pharmaceutical Product and Related 
Companies) 
11 Are the manufacturers described in the report? 
(0 no, 1 
somewhat, 2 yes) 1.5   
12 
Are licensed manufacturers, subsidiaries, and 
distributors described in the report? 
(0 no, 1 
somewhat, 2 yes) 0   
13 
Are licensed manufacturers, subsidiaries, and 
distributors differentiated from manufacturers?
(0 no, 1 
somewhat, 2 yes) 1   
Product and Patent Information 
14 
Are the originator and/or branded products 
relevant to the disease or population of study 
included in the report? 
(0 no, 1 
somewhat, 2 yes) 1   
15 
Are the specific patents of the originator 
and/or branded products mentioned? 
(0 no, 1 
somewhat, 2 yes) 1 
16 
Are generic medicines included relevant to the 
disease or population of study included in the 
report? (Or, do the patents described in 15 
specify that they are still in effect?) 
(0 no, 1 
somewhat, 2 yes) 1   
17 
Are the patents of the diagnostics which are 
used to deliver the medicines mentioned? (If 
not applicable, such as for oral dosage 
systems, give full points and note in 
comments N/A). 
(0 no, 1 
somewhat, 2 yes) 0 
Additional Criteria     
18 
Does the report include analyses of 
competition in the pharmaceutical market? 
(0 no, 1 
somewhat, 2 yes) 1.5 
The 
competition 
in the market 
is analyzed 
but not 
described in 
detail. 
19 
Does the report include opportunities and 
challenges present in the pharmaceutical 
market? 
(0 no, 1 
somewhat, 2 yes) 1.5 
The 
opportunities 
and 
challenges 
are included 
but not 
described in 
detail. 
20 
Does the report provide a pharmaceutical 
market forecast? 
(0 no, 1 
somewhat, 2 yes) 2   
 
Criteria 21-30 Not Applicable To This Report 
 
Quality Score 
Total 
Score: 
26/40 
Important 
Notes 
References and Data Sources 
31 
Does the report reference itself/the market 
research company?  
(0 only/often, 1 
sometimes, 2 
never/rarely) 0   
32 
Does the report reference scientific, peer-
reviewed literature? 
(0 never/rarely, 1 
sometimes, 2 
often) 0   
33 
Does the report reference gray literature (non-
peer-reviewed)?  
(0 never/rarely, 1 
sometimes, 2 
often) 1 
34 
Are the limitations of the data sources 
discussed?  
(0 no, 1 
somewhat, 2 yes)   
35 
Are sources clearly cited and referenced in the 
report? 
(0 no, 1 
somewhat, 2 yes) 0.5 
Citations 
were only 
given for 
tables. 
36 
Are private sector/industry resources 
consulted? 
(0 no, 1 
somewhat, 2 yes) 2   
37 
Are public sector/government resources 
consulted? 
(0 no, 1 
somewhat, 2 yes) 2   
38 
Are provider/hospital/insurance resources 
consulted? 
(0 no, 1 
somewhat, 2 yes) 2   
39 
Were experts consulted in compiling this 
report? 
(0 no, 1 
somewhat, 2 yes) 1 
40 
Are technical contacts (with their place of 
work, sector of work, and position specified) 
included in this report? 
(0 no, 1 
somewhat, 2 yes) 1.5 
Only 
authors were 
included 
with their 
place of 
work; no 
additional 
technical 
contacts 
were given. 
Research Methodology and Presentation 
41 
Are the data sources (primary/secondary/etc.) 
clearly described and referenced?  
(0 no, 1 
somewhat, 2 yes) 1   
42 Are the data analyses described?  
(0 no, 1 
somewhat, 2 yes) 0   
43 
Is the general research methodology 
described? 
(0 no, 1 
somewhat, 2 yes) 2   
44 
Is the research methodology clear, 
comprehensive, and reproducible? 
(0 no, 1 
somewhat, 2 yes) 1 
45 Are accepted scientific units used? 
(0 never/rarely, 1 
sometimes, 2 
often/always) 2   
46 
Is accepted pharmaceutical terminology (for 
the active ingredient) used? 
(0 never/rarely, 1 
sometimes, 2 
often/always) 2   
47 
Are data graphs and figures presented in a 
clear, legible, and understandable manner? 
(0 never/rarely, 1 
sometimes, 2 
often/always) 2   
Company Background 
48 
Is the name of the market research company 
clearly presented? 
(0 no, 1 
somewhat, 2 yes) 2   
49 
Is the location/address of the market research 
company included? 
(0 no, 1 
somewhat, 2 yes) 2   
50 
Is contact information for the company and/or 
authors included? 
(0 no, 1 
somewhat, 2 yes) 2   
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